Tocqueville Asset Management L.P. increased its position in shares of BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Rating) by 37.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 39,400 shares of the company’s stock after acquiring an additional 10,750 shares during the quarter. Tocqueville […]
BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Rating) – Equities researchers at HC Wainwright dropped their Q2 2023 EPS estimates for BioXcel Therapeutics in a research note issued on Thursday, May 11th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn ($1.77) per share for the quarter, down from their previous estimate of […]
BioXcel Therapeutics (NASDAQ:BTAI – Get Rating) had its target price lowered by Guggenheim from $50.00 to $46.00 in a report issued on Tuesday, The Fly reports. Other equities analysts have also issued reports about the company. Jefferies Financial Group lowered BioXcel Therapeutics from a buy rating to a hold rating and increased their price target […]
BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Rating)’s share price rose 6.8% during trading on Friday . The stock traded as high as $22.60 and last traded at $22.59. Approximately 153,009 shares traded hands during trading, a decline of 68% from the average daily volume of 478,716 shares. The stock had previously closed at $21.15. Analysts […]
BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Rating) saw a significant increase in short interest in March. As of March 31st, there was short interest totalling 3,600,000 shares, an increase of 21.2% from the March 15th total of 2,970,000 shares. Currently, 18.3% of the shares of the company are sold short. Based on an average trading […]